Chi-Med Initiates P-III FRESCO-2 Study of Fruquintinib in Metastatic Colorectal Cancer
Shots:
- The P-III FRESCO-2 study involves assessing of fruquintinib vs PBO in patients with m-CRC in ~130 sites across 10 countries
- The company has initiated the study in the US- EU- and Japan- while the first has been dosed in the US on Sept 03- 2020. The clinical data from P-III FRESCO study in Chinese patients and the global FRESCO-2 study would support NDA submission to the US FDA for patients with advanced m-CRC
- EMA & PMDA has reviewed and endorsed the design of FRESCO-2 study. Fruquintinib is a highly selective and VEGFR 1/2/3 inhibitor and has received NMPA’s approval in Sept’2018 and commercially in late Nov’2018 by Eli Lilly under the name Elunate
Ref: Chi-Med | Image: Oncology News Australia
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com